Despite advances in the treatment of non-small cell lung cancers (NSCLC), for example, the development of EGFR tyrosine kinase inhibitors (EGFR TKIs) for patients with activating EGFR mutations, survival rates for patients with mutant-KRas lung cancer are poor. Here, EGFR is linked to lung cancer.